Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

ients with CD20+ non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL).

About the HannaH trial

HannaH is a Phase III, open-label trial involving 596 women with HER2-positive early breast cancer. The trial was designed to compare trastuzumab concentration in the blood (pharmacokinetics), efficacy (pathologic complete response) and safety of Herceptin SC to that of Herceptin IV.

The trial met its co-primary endpoints that were trastuzumab concentration in the blood (serum concentrations) and efficacy. Secondary endpoints included event-free survival and overall survival. In the trial the most common side effects seen were infections and abnormal blood counts (anaemia and low white blood count) similar to other trials with chemotherapy and Herceptin IV.

About Herceptin subcutaneous delivery

Herceptin SC uses Enhanze™ Technology, developed by Halozyme(R) which enables the injection of large volumes of a medication under the skin (subcutaneous) and enhances pharmacokinetics. It works by reversibly breaking down a gel-like substance (hyaluronan) that forms a barrier in the tissues between cells under the skin.

About Breast Cancer

Breast cancer is the most common cancer among women worldwide. Each year about 1.4 million new cases of breast cancer are diagnosed worldwide, and over 450,000 people will die of the disease annually.  

In HER2-positive breast cancer, increased quantities of the HER2 receptor are present on the surface of the tumour cells. This is known as 'HER2 positivity' and affects approximately 15-20 percent of people with breast cancer.

Halozyme Roche Collaboration

In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme's proprietary Enhanze™ technology to Roche's biological therapeutic compounds. Under the terms of the agreement, Roche made an initial payment to Halozyme
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... ... September 01, 2015 , ... According to a ... with type 2 diabetes that participated in a three year study about weight loss ... the line if they elected weight loss surgery at the onset of the trial. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... its annual Light it Red for Lymphoma awareness initiative, the nation’s premier and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art ... Behind the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, ... the collaboration between fashion and professional hair, makeup and nail design. , The ...
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2
... , Nurtur Receives Accreditation for Five Population Health ... Health Impact Institute (PHII), a non-profit 501(c)(3) organization, is pleased ... Healthcare Transparency Accreditation Program, v 1.0 (H-TAP(TM)) after two years ... based in Farmington, CT is the first organization to receive ...
... studies suggest that adding flaxseed oil to the diet could ... with diabetes, according to a report to be published in ... Health . Mer Harvi and colleagues at the National ... diabetes on bone health and evaluated how flaxseed oil in ...
... die than whites, study finds , MONDAY, Nov. 23 ... don,t explain why black colon cancer patients have lower ... an effort to determine why blacks have lower survival ... cancers, investigators have explored a variety factors, such as ...
... Calif., Nov. 23 , Dear Isis Supporters and Shareholders, , ... support of Isis. We believe we are at one of ... at the end of the beginning of creating a unique company ... of the issues haunting the pharmaceutical industry. , Our ...
... ... Best New Technology Provider for its QlikView Business Intelligence Software , ... Radnor, PA (PRWEB) ... today announced that it was recognized with the Healthcare IT Innovation™ Award in ...
... , NEW YORK, Nov. 23 With ... few extra inches and pounds. Lady Foot Locker recommends ... do the work. With the right footwear, it can do exactly ... Reebok,s EasyTone and Skechers, Shape Ups , can ...
Cached Medicine News:Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Flaxseed oil and osteoporosis 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 4Health News:Make the Most of Your Holiday Haul with Lady Foot Locker 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: